ABBV$208.84

AbbVie Inc.

Last Updated

May 25, 2026about 2 months ago

Moat & Trend

Management

Strong

AI Impact

Competitive Radar

Moat Score

63/100

Executive Summary

AbbVie has a real but uneven moat built on patent-protected biologics, physician loyalty, and scale in complex drug development and manufacturing. Its strongest franchises remain hard to displace, but the business is still exposed to patent expiry and biosimilar erosion, which has already pressured legacy products like Humira. Newer assets such as Skyrizi and Rinvoq, plus ongoing portfolio expansion, help offset the decay, yet they do not fully restore the older moat profile. Overall, AbbVie remains structurally advantaged versus most mid-cap drug makers, but its advantages are narrower and less durable than a true wide-moat pharma leader. The moat is therefore meaningful, but trending slightly weaker.

Network Effects

Limited Research Ecosystem

Pillar Strength

3.5/10

AbbVie shows only modest network effects. The ARCH data and analytics platform can improve internal R&D productivity by connecting scientists, datasets, CROs, and academic collaborators, and each added tool or data source can raise the value of the environment. However, this is not a classic external network where customers become more valuable as the user base grows. Most participants are internal or tightly managed partners, and the benefits are primarily operational rather than self-reinforcing at scale. Competing pharma companies can also build similar collaboration layers. As a result, AbbVie has an ecosystem advantage in research, but it is weak, bounded, and not a major source of long-term moat strength.

Switching Costs

Patient Lock-In Friction

Pillar Strength

7/10

AbbVie benefits from meaningful switching costs in several therapeutic areas, especially chronic immunology treatments where patients and physicians are reluctant to change a stable regimen. Switching can require new prior authorization, monitoring, dose titration, and administrative work, while any loss of disease control can be costly and disruptive. Support programs and long-standing physician familiarity reinforce inertia. That said, switching costs are not absolute: payers can and do push patients toward biosimilars or alternative branded therapies, and regulatory pathways make substitution easier than in many other industries. The result is real but imperfect lock-in. AbbVie’s products enjoy strong retention when they are clinically successful, yet the barrier is not high enough to fully prevent competitive erosion.

Intangible Assets

Powerful Patent Fortress

Pillar Strength

8.5/10

Intangible assets are the core of AbbVie’s moat. The company relies on patents, regulatory exclusivity, biologic complexity, brand recognition among specialists, and proprietary know-how in drug development and commercialization. These protections can create meaningful pricing power and delay direct competition for years. AbbVie’s portfolio has historically produced blockbuster cash flows because rivals cannot quickly replicate the underlying molecules, trial data, manufacturing processes, or physician trust. The weakness is durability: patents eventually expire, and biosimilars can rapidly compress margins once exclusivity ends, as Humira demonstrated. Even so, AbbVie remains one of the stronger examples of IP-driven advantage in large-cap healthcare. Its intangible asset base is substantial, legally defended, and central to economics across the portfolio.

Cost Advantages

Scale Without Dominance

Pillar Strength

6/10

AbbVie has a moderate cost advantage stemming from scale in R&D, clinical development, procurement, manufacturing, and global distribution. Large fixed costs can be spread across a broad portfolio, and the company’s supply chain sophistication helps reduce disruption and operating inefficiency. In biologics, scale also matters because manufacturing complexity and quality control raise the bar for smaller rivals. Still, AbbVie does not enjoy a clearly superior structural cost position versus the best large-cap pharma peers. Companies such as Lilly, J&J, Merck, and Pfizer also operate at scale and can match many of the same process benefits. AbbVie’s advantage is real but incremental rather than decisive, making it supportive of the moat without being a primary source of durability.

Efficient Scale

Oligopoly Franchise Markets

Pillar Strength

6.5/10

AbbVie operates in therapeutic markets that are often oligopolistic, with a limited number of large, research-intensive competitors able to fund development, navigate regulation, and win physician trust. That creates a meaningful efficient-scale effect, because new entrants face high capital requirements, long timelines, and clinical uncertainty. In specific disease categories, only a few companies can plausibly compete for share. However, the broader biopharma landscape is still highly contested, and AbbVie must defend against several elite rivals across immunology, oncology, neuroscience, and aesthetics. Biosimilar entrants also reduce the exclusivity of legacy franchises. So while entry barriers are significant, they do not create a natural monopoly. AbbVie’s scale helps, but the market remains competitive enough to limit this pillar’s strength.

Management Quality Assessment

Evaluating leadership track record, capital allocation, and governance

Verdict

Strong

AbbVie’s management has a solid record of steering a complex post-Humira transition. Founder-CEO Richard Gonzalez ran the company from its 2013 spin-off through the Humira peak and the biosimilar reset, then handed leadership to internal successor Robert Michael, CEO since July 2024 and chairman from July 2025. Capital allocation has been generally disciplined: ROIC has stayed in the low-to-high teens, dividends have risen steadily, and buybacks continue, while M&A has produced both wins (Pharmacyclics, Capstan) and one costly miss (aborted Shire). Insider ownership appears low at roughly 1–2% and trending data are unclear. CEO pay near $32.5M is high but mostly equity-based; no major governance red flags stand out.

Key Highlights

Richard Gonzalez led AbbVie from its 2013 spin-off through 11 years as CEO, overseeing Humira’s growth and the difficult transition into biosimilar competition before an internal handoff to Robert Michael.
AbbVie’s ROIC has remained strong, rising into the high teens in 2022-2024 and still running above 11% in 2026, suggesting management has preserved capital efficiency.
M&A has been mixed but mostly strategic: Pharmacyclics was a meaningful win, recent bolt-ons like Capstan fit the pipeline strategy, while the abandoned Shire bid cost a $1.6 billion breakup fee.
Shareholders have received substantial cash returns through a growing dividend and ongoing repurchases, but insider ownership is only about 1-2%, so direct managerial economic alignment is limited.
CEO compensation is large at roughly $32.5 million annually, but it is heavily stock-based and tied to performance metrics, which reduces but does not eliminate pay-for-performance concerns.

AI Impact Assessment

Evaluating how AI strengthens or disrupts existing moat pillars

AI Opportunity

6/ 10

AI Threat

5/ 10

Net AI Impact

+1Neutral

Net Reinforcer. AbbVie’s moat is still anchored by patent-protected drugs, regulatory barriers, and a large R&D engine; AI mainly strengthens the R&D and clinical-development pillar rather than creating a new source of lock-in. The ARCH platform, with 200+ data sources and more than two billion data points, plus AbbVie’s access to extensive genomics data, can plausibly improve target discovery, trial design, and document automation. That is real operational leverage, but it is not easily exclusive because data-integration tools and model layers are becoming more standardized across pharma. The main uncertainty is conversion: whether AI meaningfully increases approved-drug output and timelines faster than peers, or simply narrows costs without changing relative competitiveness.

Sign in to see the full analysis

The Strategic Factor Breakdown, Management Quality Assessment, and AI Impact Assessment are available to registered users — it's free.

Last Updated

Apr 3, 20263 months ago

Target Price

Analyst Consensus

Buy19 analysts

FAIR VALUE

Financial Strength

Financial Score

50/100

Executive Summary

AbbVie Inc. is poised for a significant turnaround, with strong analyst projections indicating a robust recovery in revenue and EPS growth from 2026, driven by an accelerating top-line and margin expansion, supported by a 'Buy' consensus. Historically, the company has faced challenges with inconsistent revenue growth, a multi-year decline in net income, and compressed operating margins due to increased R&D and significant non-operating expenses. The balance sheet exhibits concerning trends, including decreasing cash, rising liabilities, and negative shareholders' equity, signaling deteriorating liquidity and high leverage. While operating and free cash flow have declined, they remain substantial. Liquidity ratios are weak, and leverage has been volatile, yet efficiency metrics are stable. The projected growth offers a sharp contrast to recent performance, suggesting the financial profile is transitioning from a period of significant stress to one with strong expected recovery, despite current solvency concerns.

Income Statement

Revenue · Margins · Profitability

Section Score

5/10

AbbVie Inc. exhibits inconsistent growth trends. Revenue saw a dip in FY2023 but recovered in FY2024 and FY2025, showing an 8.57% growth in the latest year. However, net income has experienced a significant multi-year decline, from $11.5 billion in FY22 to $4.2 billion in FY25, indicating that top-line recovery is not translating to bottom-line gains. Margins are volatile; gross margin dipped in FY23 but recovered, while operating margin has compressed significantly from 31.89% to 24.65% over the period, suggesting increased operating costs. A major flag is the substantial increase in R&D and Other Operating Expenses in FY2024, coupled with persistently high "Other Non-Operating Income (Expense)" which consistently acts as a significant drag on pretax income. Assuming this is a pharmaceutical company, such R&D spending could be expected, but the lack of commensurate profit growth and the large non-operating expenses are concerning risks. The effective tax rate also swung wildly, from 22.03% to -15.34% then to 35.83%, pointing to potential one-off tax benefits or charges impacting reported net income.

Financials are in millions USD unless otherwise specified

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	61,160	56,334	54,318	58,054	56,197
Revenue Growth (YoY)	8.57%	3.71%	-6.44%	3.30%	22.69%
Net Income	4,226	4,278	4,863	11,836	11,542
Net Income Growth	-1.22%	-12.03%	-58.91%	2.55%	150.04%
Profit Margin	6.92%	7.61%	8.97%	20.40%	20.55%

Data as of Dec 31, 2025

Balance Sheet

Assets · Liabilities · Equity

Section Score

3/10

AbbVie's balance sheet exhibits concerning trends, particularly in solvency and equity quality. Cash and short-term investments have decreased significantly, from $12,816 million in FY2023 to $5,257 million in FY2025, while total current liabilities have risen consistently, reaching $43,289 million in FY2025. This indicates deteriorating liquidity. Total liabilities have steadily increased to $137,188 million, exceeding total assets of $133,960 million in FY2025. This led to a negative shareholders' equity of -$3,270 million in FY2025, a substantial decline from $15,408 million in FY2021. The increasing reliance on debt, with total debt at $67,496 million in FY2025, further strains the financial structure. These trends suggest significant leverage and a weakening equity base.

Financials are in millions USD unless otherwise specified

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Current Assets	29,062	25,582	33,002	28,463	27,928
Total Assets	133,960	135,161	134,711	138,805	146,529
Total Current Liabilities	43,289	38,749	37,841	29,538	35,194
Total Liabilities	137,188	131,797	124,314	121,518	131,093

Data as of Dec 31, 2025

Cash Flow Statement

Operations · Investing · Financing

Section Score

5.5/10

AbbVie's operating cash flow (CFO) has shown a declining trend since 2022, dropping from $24.9 billion to $19.0 billion in 2025, with growth turning negative in 2023 and 2024. Despite this, CFO remains substantial. Free cash flow (FCF) mirrors this decline, falling from $24.2 billion in 2022 to $17.8 billion in 2025, indicating reduced cash generation after capital expenditures. The FCF margin also compressed from 41.77% to 29.13% over the period. Investing activities saw significant outflows, particularly in 2024 due to large business acquisitions ($20.5 billion), suggesting aggressive external growth. Financing activities consistently show substantial outflows driven by dividends and debt repayment, though long-term debt issuance in 2024 partially offset this. The company maintains a commitment to returning capital to shareholders through dividends, which have steadily increased.

Financials are in millions USD unless otherwise specified

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow	19,030	18,806	22,839	24,943	22,777
Operating Cash Flow Growth	1.19%	-17.66%	-8.43%	9.51%	29.50%
Free Cash Flow	17,816	17,832	22,062	24,248	21,990
Free Cash Flow Growth	-0.09%	-19.17%	-9.01%	10.27%	30.97%

Data as of Dec 31, 2025

Key Ratios

Liquidity · Leverage · Efficiency · Returns

Section Score

5/10

AbbVie's liquidity appears challenging, with both current and quick ratios consistently below 1.0, indicating potential difficulties in covering short-term obligations. Leverage metrics, particularly the Debt/Equity ratio, have shown considerable volatility, peaking significantly in FY2024 and subsequently turning negative, suggesting a shifting capital structure. Efficiency, as reflected by asset turnover, has remained relatively stable, hovering around 0.40-0.45. Inventory turnover has seen a slight decline in the later periods. Profitability and returns present a mixed picture; while ROE has seen extraordinary spikes in recent years, other metrics like ROA and ROIC have fluctuated. The exceptionally high and volatile ROE, alongside negative PB and Debt/Equity ratios, points to a complex financial profile that warrants close attention.

Ratios are dimensionless unless otherwise noted

Metric	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 2, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Debt / Equity Ratio	-19.03	-19.03	17.94	5.02	3.42	4.16
Quick Ratio	0.41	0.41	0.43	0.63	0.69	0.56
Current Ratio	0.67	0.67	0.66	0.87	0.96	0.79
ROEReturn on Equity (ROE)	6,225.00%	6,225.00%	62.29%	35.20%	72.40%	80.95%
ROAReturn on Assets (ROA)	7.19%	7.19%	7.81%	7.27%	11.16%	10.73%
ROICReturn on Invested Capital (ROIC)	10.10%	10.10%	11.16%	10.18%	14.60%	13.51%
ROCEReturn on Capital Employed (ROCE)	16.12%	16.12%	9.45%	12.38%	16.43%	15.37%

Data as of Apr 2, 2026

Growth

Revenue · EPS · Valuation · Estimates

Section Score

6.5/10

AbbVie's financial trajectory shows a clear transition from historical actuals (up to FY 2025) to analyst forecasts (FY 2026 and FY 2027). Historically, revenue growth has been volatile, with a significant dip in 2023 (-6.44%) and 2024 (-12.13% for EPS) after strong 2021-2022 performance. However, analysts project a robust recovery, with revenue growth accelerating to 11.9% in 2026 and EPS growth surging to 528.83% in the same year, followed by sustained growth. This implies strong margin expansion. The forward P/E of 14.07 for 2026 and 12.72 for 2027 appears reasonable given the significant projected EPS rebound. Analyst sentiment is positive with a "Buy" consensus and an average price target of $247.74, indicating confidence in the projected turnaround. Coverage depth is solid with 19 analysts, and while the recommendation trend shows minor fluctuations, it generally remains stable with a strong leaning towards "Buy" or "Strong Buy" ratings.

Analyst Price Targets

Low$194-7.11%

Median$250+19.71%

Average$247.74+18.63%

High$299+43.17%

BuyConsensus rating based on analyst coverage

19 analysts

Recommendation Trends

Rating	Mar '26	Feb '26	Jan '26	Dec '25	Nov '25	Oct '25
Strong Buy	4	4	5	5	4	6
Buy	10	10	9	9	11	12
Hold	6	6	7	5	6	5
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	20	20	21	19	21	23

Financial Forecast

Metric	FY 2027	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	74.00B	68.44B	61.16B	56.33B	54.32B	58.05B	56.20B
Revenue Growth	+8.13%	+11.90%	+8.57%	+3.71%	-6.44%	+3.30%	+22.69%
EPS	16.42	14.84	2.36	2.39	2.72	6.63	6.45
EPS Growth	+10.64%	+528.83%	-1.26%	-12.13%	-58.97%	+2.79%	+137.13%
Forward P/E	12.7x	14.1x	—	—	—	—	—

Revenue in USD · EPS per share · Price targets in USD

Data as of FY 2025 · Italic columns are analyst estimates

Fair Value Estimation

EV/EBITDA · +6.9% Margin of Safety · Fairly Valued

AI Fair Value Estimate (EV/EBITDA)

$223.32vs$208.84

Margin of Safety+6.9%

Fairly Valued — Trading near intrinsic value

AbbVie is a mature pharmaceutical company with significant capital expenditures and depreciation, making EV/EBITDA an appropriate valuation model as it neutralizes the impact of different capital structures and non-cash expenses. Given the negative shareholder equity, P/B is not suitable, and while FCF is positive, EV/EBITDA is more robust for comparing against peers in a capital-intensive industry. The dividend yield is above 1.5% but the payout ratio is very high, suggesting that DDM might not be stable for future dividend growth assumptions.

AI Valuation Verdict

AbbVie is assessed using the EV/EBITDA model, which is suitable for capital-intensive pharmaceutical companies as it mitigates distortions from depreciation and varying capital structures. The estimated fair value per share is $223.32, resulting in a 6.93% margin of safety, indicating the stock is Fairly Valued. A key assumption is the average EV/EBITDA multiple derived from comparable companies: Eli Lilly (28.00x), Johnson & Johnson (15.01x), and Bristol-Myers Squibb (8.2x). The valuation is sensitive to these multiples; a higher average could suggest undervaluation, while a lower average might imply overvaluation. Analyst consensus currently leans towards a 'Buy' with a median price target of $250, aligning with a slightly higher valuation than our current estimate. Further increases in profitability or a favorable shift in market multiples for the pharmaceutical sector could lead to a higher intrinsic value.

Comparable Companies

Company	Ticker	Metric	Multiple	Implied Price
Eli Lilly and Company	LLY	EBITDA	28.00	$625.68
Johnson & Johnson	JNJ	EBITDA	15.01	$224.25
Bristol-Myers Squibb Company	BMY	EBITDA	8.2	$96

Sign in to see the full analysis

The Income Statement, Balance Sheet, Cash Flow, Key Ratios, Forecast, and Fair Value analysis are available to registered users — it's free.

Sign In to Run AI-Powered Technical Analysis

Create a free account to run a fresh technical analysis across three timeframes — short, medium, and long term.

Disclaimer: The analysis on this page is generated by AI and is provided for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any security. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decisions.